Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 39 | 2022 | 55 | 11.710 |
Why?
|
| Liver Neoplasms | 31 | 2022 | 103 | 10.510 |
Why?
|
| Portal Vein | 30 | 2022 | 40 | 9.340 |
Why?
|
| Liver | 21 | 2022 | 173 | 7.180 |
Why?
|
| Liver Regeneration | 17 | 2022 | 24 | 5.390 |
Why?
|
| Colorectal Neoplasms | 13 | 2021 | 82 | 3.880 |
Why?
|
| Ligation | 22 | 2022 | 32 | 2.700 |
Why?
|
| Embolization, Therapeutic | 6 | 2021 | 26 | 2.520 |
Why?
|
| Laparoscopy | 6 | 2021 | 145 | 1.850 |
Why?
|
| Hepatic Stellate Cells | 2 | 2020 | 9 | 1.410 |
Why?
|
| Postoperative Complications | 13 | 2022 | 957 | 1.340 |
Why?
|
| Liver Diseases | 2 | 2018 | 41 | 1.200 |
Why?
|
| Cause of Death | 3 | 2017 | 65 | 1.160 |
Why?
|
| Registries | 9 | 2019 | 189 | 1.120 |
Why?
|
| Liver Failure | 4 | 2019 | 11 | 1.020 |
Why?
|
| Humans | 56 | 2024 | 29361 | 1.000 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2021 | 32 | 0.970 |
Why?
|
| Treatment Outcome | 20 | 2021 | 3476 | 0.920 |
Why?
|
| Hypertrophy | 5 | 2022 | 19 | 0.870 |
Why?
|
| Hypoxia | 2 | 2020 | 60 | 0.860 |
Why?
|
| Organ Size | 9 | 2019 | 107 | 0.810 |
Why?
|
| Sarcopenia | 1 | 2021 | 26 | 0.790 |
Why?
|
| Retrospective Studies | 17 | 2022 | 3273 | 0.770 |
Why?
|
| Male | 36 | 2021 | 15637 | 0.760 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 65 | 0.720 |
Why?
|
| Neovascularization, Pathologic | 1 | 2020 | 56 | 0.720 |
Why?
|
| Neuroendocrine Tumors | 5 | 2019 | 17 | 0.710 |
Why?
|
| Kidney Transplantation | 5 | 2021 | 125 | 0.700 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 7 | 0.690 |
Why?
|
| Hepatomegaly | 1 | 2018 | 4 | 0.680 |
Why?
|
| Reperfusion Injury | 1 | 2018 | 8 | 0.670 |
Why?
|
| Middle Aged | 26 | 2019 | 9823 | 0.660 |
Why?
|
| Publication Bias | 1 | 2018 | 7 | 0.660 |
Why?
|
| Antioxidants | 1 | 2018 | 57 | 0.640 |
Why?
|
| Bibliometrics | 1 | 2018 | 24 | 0.640 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 126 | 0.640 |
Why?
|
| Oxidative Stress | 1 | 2018 | 124 | 0.640 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 333 | 0.640 |
Why?
|
| Female | 31 | 2021 | 16211 | 0.620 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 22 | 0.620 |
Why?
|
| Length of Stay | 5 | 2021 | 317 | 0.570 |
Why?
|
| Therapies, Investigational | 1 | 2016 | 7 | 0.560 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 142 | 0.560 |
Why?
|
| Aged | 20 | 2019 | 9447 | 0.550 |
Why?
|
| Graft Rejection | 4 | 2008 | 76 | 0.490 |
Why?
|
| Catheter Ablation | 1 | 2015 | 78 | 0.490 |
Why?
|
| Animals | 8 | 2021 | 4577 | 0.480 |
Why?
|
| Liver Transplantation | 3 | 2015 | 79 | 0.470 |
Why?
|
| Hepatic Veins | 4 | 2022 | 7 | 0.460 |
Why?
|
| Blood Loss, Surgical | 3 | 2019 | 64 | 0.450 |
Why?
|
| Prognosis | 8 | 2020 | 840 | 0.440 |
Why?
|
| Time Factors | 9 | 2019 | 1618 | 0.430 |
Why?
|
| Risk Factors | 10 | 2019 | 2446 | 0.430 |
Why?
|
| Feasibility Studies | 4 | 2016 | 227 | 0.410 |
Why?
|
| Survival Rate | 6 | 2018 | 349 | 0.380 |
Why?
|
| Operative Time | 4 | 2019 | 80 | 0.380 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 1829 | 0.370 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 340 | 0.360 |
Why?
|
| Tissue Donors | 2 | 2021 | 74 | 0.360 |
Why?
|
| Models, Animal | 3 | 2020 | 126 | 0.360 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 189 | 0.350 |
Why?
|
| Random Allocation | 3 | 2018 | 146 | 0.350 |
Why?
|
| Isoantibodies | 2 | 2006 | 11 | 0.350 |
Why?
|
| Intestinal Neoplasms | 2 | 2018 | 5 | 0.340 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 30 | 0.330 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 10 | 0.330 |
Why?
|
| Swine | 2 | 2018 | 80 | 0.320 |
Why?
|
| Pancreas Transplantation | 2 | 2021 | 16 | 0.320 |
Why?
|
| Death | 1 | 2008 | 48 | 0.320 |
Why?
|
| Vascular Surgical Procedures | 2 | 2019 | 24 | 0.310 |
Why?
|
| Adult | 15 | 2019 | 8604 | 0.300 |
Why?
|
| Rats, Wistar | 2 | 2017 | 40 | 0.300 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 132 | 0.300 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 260 | 0.290 |
Why?
|
| Patient Selection | 4 | 2018 | 232 | 0.290 |
Why?
|
| Switzerland | 3 | 2021 | 9 | 0.290 |
Why?
|
| Plasmapheresis | 1 | 2006 | 14 | 0.280 |
Why?
|
| Rats | 2 | 2020 | 858 | 0.280 |
Why?
|
| HLA Antigens | 1 | 2006 | 17 | 0.280 |
Why?
|
| Antibody Formation | 1 | 2006 | 40 | 0.280 |
Why?
|
| Risk Assessment | 5 | 2019 | 678 | 0.270 |
Why?
|
| Philosophy, Medical | 1 | 2004 | 1 | 0.250 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2024 | 5 | 0.240 |
Why?
|
| Spirituality | 1 | 2004 | 66 | 0.240 |
Why?
|
| Tissue and Organ Procurement | 3 | 2012 | 34 | 0.220 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 324 | 0.210 |
Why?
|
| Ultrasonography | 3 | 2021 | 226 | 0.210 |
Why?
|
| Cell Proliferation | 2 | 2020 | 202 | 0.210 |
Why?
|
| Databases, Factual | 3 | 2019 | 330 | 0.210 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 13 | 0.210 |
Why?
|
| Organ Transplantation | 1 | 2021 | 35 | 0.200 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 47 | 0.200 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 25 | 0.200 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1113 | 0.200 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 218 | 0.200 |
Why?
|
| Biomarkers | 3 | 2020 | 692 | 0.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 100 | 0.190 |
Why?
|
| Hospitals | 1 | 2021 | 157 | 0.190 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2020 | 3 | 0.190 |
Why?
|
| Adrenalectomy | 1 | 2019 | 2 | 0.180 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 5 | 0.180 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 6 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 75 | 0.180 |
Why?
|
| Brazil | 2 | 2016 | 37 | 0.180 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 80 | 0.180 |
Why?
|
| Parenchymal Tissue | 1 | 2019 | 1 | 0.170 |
Why?
|
| Conversion to Open Surgery | 1 | 2019 | 3 | 0.170 |
Why?
|
| Hospital Mortality | 3 | 2015 | 141 | 0.170 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 9 | 0.170 |
Why?
|
| Preoperative Period | 1 | 2019 | 65 | 0.170 |
Why?
|
| Liver Function Tests | 4 | 2017 | 24 | 0.170 |
Why?
|
| Gallium Radioisotopes | 1 | 2018 | 1 | 0.170 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 13 | 0.170 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2018 | 13 | 0.170 |
Why?
|
| Paracrine Communication | 1 | 2018 | 7 | 0.170 |
Why?
|
| Cytoprotection | 1 | 2018 | 8 | 0.170 |
Why?
|
| Culture Media, Conditioned | 1 | 2018 | 37 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 28 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 21 | 0.170 |
Why?
|
| Hepatocytes | 1 | 2018 | 10 | 0.170 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 20 | 0.170 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 36 | 0.170 |
Why?
|
| Anesthesia | 1 | 2018 | 34 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 37 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 42 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 59 | 0.160 |
Why?
|
| Gastric Bypass | 1 | 2018 | 52 | 0.160 |
Why?
|
| Models, Biological | 1 | 2020 | 344 | 0.160 |
Why?
|
| Logistic Models | 3 | 2016 | 407 | 0.160 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 265 | 0.160 |
Why?
|
| Liver Circulation | 1 | 2017 | 3 | 0.160 |
Why?
|
| Portal Pressure | 1 | 2017 | 3 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 770 | 0.160 |
Why?
|
| Survival Analysis | 2 | 2017 | 298 | 0.150 |
Why?
|
| Apoptosis | 1 | 2018 | 251 | 0.150 |
Why?
|
| Hyperplasia | 1 | 2017 | 14 | 0.150 |
Why?
|
| Fatty Liver | 1 | 2017 | 30 | 0.150 |
Why?
|
| Melanoma | 1 | 2017 | 52 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 340 | 0.150 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 788 | 0.140 |
Why?
|
| Cell Hypoxia | 1 | 2016 | 11 | 0.140 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 12 | 0.140 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 12 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 178 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2018 | 483 | 0.140 |
Why?
|
| Obesity | 1 | 2018 | 290 | 0.140 |
Why?
|
| Primary Graft Dysfunction | 1 | 2015 | 4 | 0.140 |
Why?
|
| Methyl Ethers | 1 | 2015 | 6 | 0.130 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 35 | 0.130 |
Why?
|
| Anesthetics, Intravenous | 1 | 2015 | 13 | 0.130 |
Why?
|
| Anesthetics, Inhalation | 1 | 2015 | 11 | 0.130 |
Why?
|
| Propofol | 1 | 2015 | 17 | 0.130 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 726 | 0.130 |
Why?
|
| Cohort Studies | 3 | 2017 | 1939 | 0.130 |
Why?
|
| Safety | 1 | 2014 | 45 | 0.130 |
Why?
|
| Surgeons | 1 | 2016 | 76 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 132 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 68 | 0.120 |
Why?
|
| Viscera | 1 | 2013 | 1 | 0.120 |
Why?
|
| Renal Artery | 1 | 2013 | 6 | 0.120 |
Why?
|
| Vascular Patency | 1 | 2013 | 15 | 0.120 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 9 | 0.120 |
Why?
|
| Aneurysm | 1 | 2013 | 11 | 0.120 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 29 | 0.110 |
Why?
|
| Endovascular Procedures | 1 | 2013 | 33 | 0.110 |
Why?
|
| Stents | 1 | 2013 | 76 | 0.110 |
Why?
|
| Blood Transfusion | 1 | 2012 | 64 | 0.110 |
Why?
|
| Bilirubin | 2 | 2016 | 6 | 0.110 |
Why?
|
| Linear Models | 1 | 2012 | 254 | 0.100 |
Why?
|
| Resource Allocation | 1 | 2011 | 6 | 0.100 |
Why?
|
| Health Care Rationing | 1 | 2011 | 7 | 0.100 |
Why?
|
| End Stage Liver Disease | 1 | 2011 | 13 | 0.100 |
Why?
|
| Liver Cirrhosis | 2 | 2012 | 60 | 0.090 |
Why?
|
| Histocompatibility Testing | 1 | 2009 | 3 | 0.090 |
Why?
|
| HLA-C Antigens | 1 | 2009 | 9 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 175 | 0.080 |
Why?
|
| Antilymphocyte Serum | 1 | 2008 | 3 | 0.080 |
Why?
|
| Alemtuzumab | 1 | 2008 | 4 | 0.080 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2008 | 10 | 0.080 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2007 | 2 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 45 | 0.080 |
Why?
|
| Blood Vessels | 1 | 2007 | 15 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 59 | 0.080 |
Why?
|
| Graft Survival | 1 | 2008 | 98 | 0.080 |
Why?
|
| Heart Transplantation | 1 | 2007 | 38 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2009 | 161 | 0.080 |
Why?
|
| Incidence | 2 | 2021 | 756 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 113 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 1 | 2008 | 79 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 170 | 0.070 |
Why?
|
| HLA-DP Antigens | 1 | 2006 | 1 | 0.070 |
Why?
|
| Complement C4b | 1 | 2006 | 2 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 4851 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2018 | 427 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2006 | 99 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2021 | 1812 | 0.060 |
Why?
|
| Religion and Medicine | 1 | 2004 | 22 | 0.060 |
Why?
|
| Anesthesia, Intravenous | 1 | 2024 | 8 | 0.060 |
Why?
|
| Anesthesia, General | 1 | 2024 | 30 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 1220 | 0.060 |
Why?
|
| Hospitals, University | 2 | 2018 | 39 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2022 | 27 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 104 | 0.050 |
Why?
|
| Naphthoquinones | 1 | 2021 | 4 | 0.050 |
Why?
|
| Benzofurans | 1 | 2021 | 7 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2021 | 41 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2021 | 23 | 0.050 |
Why?
|
| Pancreas | 1 | 2021 | 32 | 0.050 |
Why?
|
| Mice | 2 | 2021 | 1620 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2021 | 54 | 0.050 |
Why?
|
| Cold Ischemia | 2 | 2011 | 3 | 0.050 |
Why?
|
| Contrast Media | 1 | 2021 | 125 | 0.050 |
Why?
|
| Mitotane | 1 | 2019 | 1 | 0.050 |
Why?
|
| Kidney | 1 | 2021 | 173 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 135 | 0.040 |
Why?
|
| Argentina | 1 | 2019 | 2 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2019 | 14 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2018 | 5 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 24 | 0.040 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2018 | 18 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 12 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2018 | 6 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 81 | 0.040 |
Why?
|
| United States | 2 | 2018 | 2332 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 364 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 101 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2019 | 100 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 14 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 290 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 56 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2017 | 36 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2019 | 288 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 46 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2017 | 159 | 0.040 |
Why?
|
| Edema | 1 | 2017 | 38 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 1184 | 0.040 |
Why?
|
| Sarcoma | 1 | 2017 | 65 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 101 | 0.040 |
Why?
|
| Italy | 1 | 2016 | 16 | 0.040 |
Why?
|
| Medical Audit | 1 | 2016 | 7 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 184 | 0.040 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 6 | 0.040 |
Why?
|
| Rabbits | 1 | 2017 | 283 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 391 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 845 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 67 | 0.030 |
Why?
|
| Belgium | 1 | 2015 | 3 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 18 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 76 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 340 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 285 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 521 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 329 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2013 | 24 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 638 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 625 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2011 | 15 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2012 | 78 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 67 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2009 | 13 | 0.020 |
Why?
|
| Immunization | 1 | 2009 | 47 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 400 | 0.020 |
Why?
|
| Child | 1 | 2012 | 1345 | 0.020 |
Why?
|
| Histocompatibility | 1 | 2007 | 3 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 25 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 277 | 0.020 |
Why?
|
| Wisconsin | 1 | 2006 | 5 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2006 | 10 | 0.020 |
Why?
|
| Atrophy | 1 | 2006 | 102 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2006 | 54 | 0.020 |
Why?
|